Since lysosome uptake of trastuzumab degrades HER2 receptors, resulting in cell death, the authors hypothesized that trastuzumab-AuNP-111In might be toxic to breast cancer cells in two ways, by reducing HER2 and by causing DNA damage in breast cancer cells, owing to Auger electron emission. The gene discussed is ERBB2; the disease is breast cancer.